Introduction
Obesity has been linked to poor outcomes in women with early-stage breast cancer, with studies showing increased mortality rates in obese patients. The BWEL trial seeks to explore whether weight loss can reduce the risk of cancer recurrence and mortality in this demographic.
Study Design
The BWEL trial is a randomized, controlled trial involving 3181 women with stage II-III breast cancer and a BMI >27 kg/m2. Participants are divided into two groups: one receiving a telephone-based weight loss intervention plus health education materials, and the other receiving health education materials alone. The intervention aims for a ≥10% weight loss through increased physical activity and caloric restriction, delivered over 42 sessions in 2 years.
Intervention Components
The lifestyle intervention is based on social cognitive theory and incorporates components from previous weight loss trials. It includes diet, physical activity, and behavioral strategies, with a focus on achieving a 7% study-wide weight loss. The intervention is delivered remotely via telephone by trained health coaches, supported by an online web portal.
Nutrition and Physical Activity
Participants are encouraged to follow a calorie-restricted diet, with options for high protein-low carbohydrate and Mediterranean-style meal plans. The physical activity goal is to achieve at least 150 minutes of moderate-intensity activity per week, increasing to 225-300 minutes after the first 6 months.
Behavioral Strategies
The intervention includes behavioral strategies such as self-monitoring of weight and food intake, setting behavioral goals, and using toolbox strategies to address barriers to weight loss. Participants are provided with tools like wireless scales and activity monitors to support their weight loss journey.
Conclusion
The BWEL trial aims to determine if weight loss can improve invasive disease-free survival in women with early-stage breast cancer. If successful, the intervention could be adapted for broader dissemination, potentially impacting future breast cancer treatment protocols and programs.